PDS Biotechnology (NASDAQ:PDSB) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of PDS Biotechnology (NASDAQ:PDSB) to a hold rating in a report released on Saturday,Wall Street Zen reports.

Several other equities research analysts also recently commented on the stock. HC Wainwright reiterated a “buy” rating on shares of PDS Biotechnology in a research report on Wednesday, August 26th. Weiss Ratings lowered shares of PDS Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 11th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, PDS Biotechnology presently has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Price Performance

Shares of PDSB opened at $0.81 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.57 and a debt-to-equity ratio of 2.73. The stock has a market cap of $45.08 million, a PE ratio of -1.26 and a beta of 1.46. PDS Biotechnology has a 12-month low of $0.20 and a 12-month high of $1.55. The business has a 50-day simple moving average of $0.49 and a two-hundred day simple moving average of $0.78.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Analysts anticipate that PDS Biotechnology will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of PDS Biotechnology in the second quarter worth approximately $535,000. Bank of New York Mellon Corp bought a new stake in PDS Biotechnology in the second quarter valued at approximately $60,000. Finally, Renaissance Technologies LLC increased its position in PDS Biotechnology by 25.0% during the 1st quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares during the period. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) is a clinical-stage biotechnology company developing immunotherapies designed to stimulate the immune system to recognize and attack cancer cells. The company’s research is centered on its Versamune platform, which is intended to activate and enhance T-cell responses against specific disease-associated targets.

PDS Biotechnology’s lead programs include PDS0101, an investigational therapeutic candidate designed to generate immune responses against human papillomavirus type 16 (HPV16) antigens.